Aromatase inhibitors in the pharmacotherapy of endometriosis

Barbara Gardella, Bárbara Gardella, Edoardo Rispoli, E Rispoli, Marianna Francesca Pasquali, Matteo Mauri, Valentina Musacchi, Mattia Dominoni
Expert opinion on pharmacotherapy · 2023 · vol. 24(9) , pp. 1067–1073 · doi:10.1080/14656566.2023.2209315 · PMID:37128968 · W4367669560
review OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Aromatase inhibitors are effective in treating endometriosis by suppressing estrogen synthesis, showing promise as a second-line therapy, especially for postmenopausal women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Endometriosis is a benign chronic inflammatory disease responsible for debilitating pain and decreased quality of life. The traditional treatment is based on estroprogestins, progestins, GnRH analogs, and surgery. Recently, aromatase inhibitors (AIs) demonstrated good efficacy in controlling symptoms and size of endometriotic implants, mostly because they suppress extraovarian estrogen synthesis, which can enhance the hypoestrogenic state ameliorating symptoms of endometriosis. AREAS COVERED: Phase I, II, III and IV trials, on the use of AIs used for the treatment of endometriosis, have been retrieved. The pharmacokinetics and pharmacodynamics of third-generation non-steroidal AIs have also been investigated. A MEDLINE search has been performed using the following MeSH keywords: 'endometriosis,' aromatase inhibitors,' 'therapy,' and 'treatment'. The timeframe was from 2010 up to November 2022 including reviews, systematic reviews, reports, case series, and retrospective or prospective trials. EXPERT OPINION: AIs have shown good clinical efficacy in combination with hormonal therapy in disease control, and they represent a promising second-line therapy in selected patients, yet more research is needed on alternative drug delivery systems and better control of adverse effects. In postmenopausal women in which surgery is contraindicated, AIs represent an excellent treatment option. Their application in routine clinical practice remains limited by adverse effects.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-14T06:08:20.186862+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-14T06:07:17.833701+00:00
License: CC0 · commercial use OK